Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288652 · ClinicalTrials.gov registry record · Phase 2
[S,S]-Reboxetine Dose-Range Finding Trial
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
NCT00288652 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 280 participants.
The verdict
NCT00288652, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of different doses of \[S,S\]-Reboxetine in the treatment of chronic pain following a shingles infection
Interventions
- DRUG [S,S]-Reboxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288652
The ClinicalTrials.gov registry entry for NCT00288652 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [S,S]-Reboxetine is the first listed.
NCT00288652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00288652 about?
NCT00288652 is a clinical study titled "[S,S]-Reboxetine Dose-Range Finding Trial". The purpose of this study is to determine the effectiveness of different doses of \[S,S\]-Reboxetine in the treatment of chronic pain following a shingles infection
What is the current status of trial NCT00288652?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2006-03. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00288652?
The interventions under investigation include: [S,S]-Reboxetine (DRUG).
Who is sponsoring clinical trial NCT00288652?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.